#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Peptides represent a diverse class of signaling molecules ranging from life-saving, FDA-approved therapeutics like insulin and GLP-1 agonists to unregulated, gray-market compounds marketed for longevity and performance. Evaluating these substances requires a rigorous framework centered on viable mechanisms of action, human clinical evidence, and safety profiles. While some peptides like SS31 and CJC-1295 show mechanistic promise in specific clinical contexts, they often lack robust human data for general wellness applications. Conversely, compounds like BPC-157 frequently rely on anecdotal evidence and animal studies from isolated research groups, lacking the independent validation necessary for clinical legitimacy. The prevalence of these substances in the wellness industry often stems from a misunderstanding of patent law and a susceptibility to marketing, as legitimate, effective therapies typically undergo formal clinical pipelines rather than bypassing regulation through "research use only" designations.